Faeth Therapeutics, Inc. (FTH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Faeth Therapeutics, Inc. (FTH) has a cash flow conversion efficiency ratio of -0.147x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-26.41 Million) by net assets ($179.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View Faeth Therapeutics, Inc. stock price for real-time trading data and today's change.
Faeth Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Faeth Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see FTH market cap for the company's overall valuation and market capitalisation.
Faeth Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Faeth Therapeutics, Inc. ranked by their cash flow conversion efficiency. Also see Faeth Therapeutics, Inc. asset portfolio for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SGC Energy Co Ltd
KO:005090
|
-0.033x |
|
Shinkong Textile Co Ltd
TW:1419
|
0.015x |
|
Shenzhen TXD Technology Co Ltd
SHE:002845
|
-0.017x |
|
Arrow Financial Corporation
NASDAQ:AROW
|
0.035x |
|
Beijing Advanced Digital Technology Co Ltd
SHE:300541
|
0.136x |
|
BCI Minerals Limited
F:BC3
|
-0.001x |
|
Shenzhen Properties & Resources Development Group Ltd
SHE:000011
|
-0.709x |
|
EZTEC Empreendimentos e Participações S.A
SA:EZTC3
|
0.042x |
Annual Cash Flow Conversion Efficiency for Faeth Therapeutics, Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Faeth Therapeutics, Inc. from 2018 to 2025. Review Faeth Therapeutics, Inc. (FTH) flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.59 Million | $-20.45 Million | -1.100x | -71.17% |
| 2024-12-31 | $38.39 Million | $-24.67 Million | -0.643x | -30.24% |
| 2023-12-31 | $64.89 Million | $-32.02 Million | -0.493x | -30.75% |
| 2022-12-31 | $103.41 Million | $-39.03 Million | -0.377x | -82.74% |
| 2021-12-31 | $146.51 Million | $-30.26 Million | -0.207x | +81.46% |
| 2020-12-31 | $15.89 Million | $-17.70 Million | -1.114x | -992.43% |
| 2019-12-31 | $-68.66 Million | $-8.57 Million | 0.125x | -35.27% |
| 2018-12-31 | $-53.48 Million | $-10.31 Million | 0.193x | -- |
About Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune chec… Read more